| Phase Forward to Present at the 21st Annual Piper Jaffray Health Care Conference
November 27, 2009 at 10:45 am
|
| WALTHAM, Mass.--(BUSINESS WIRE)--Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced its chairman and chief executive officer, Bob Weiler, and senior vice president and chief financial officer, Chris Menard, will present at the 21st Annual Piper Jaffray Health Care Conference at the New York Palace Hotel in New York City. The Phase Forward presentation is scheduled for Tuesday, December 1, 2009 at 12:30 p.m. ET. The p
      
 |
| ChemGenex's Marketing Authorization Application for Omacetaxine Mepesuccinate Validated by the European Medicines Agency
November 27, 2009 at 8:00 am
|
| MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that the European Medicines Agency ("EMEA") has determined that the Marketing Authorization Application ("MAA") for omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation is valid. Validation of the MAA indicates that ChemGenex’s application, submitted
 |
| Tripep: The ChronVac-C® Study Has Been Successfully Completed with Good Safety and Favorable Clinical Data
November 27, 2009 at 2:22 am
|
| STOCKHOLM, Sweden--(BUSINESS WIRE)--All samples from the 12 patients with chronic Hepatitis C genotype 1 treated with Tripep’s therapeutic vaccine ChronVac-C® have now been collected. The treatment was found to be safe, immunogenic and had transient effects on the serum levels of hepatitis C virus. This provides a proof-of-concept for the therapeutic strategy. In addition, early data from three patients who have initiated standard of care treatment after completing the clinical trial
 | | | 
|
没有评论:
发表评论